431 related articles for article (PubMed ID: 37938366)
1. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
[TBL] [Abstract][Full Text] [Related]
2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
3. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
[TBL] [Abstract][Full Text] [Related]
5. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
6. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Budd J; Cusi K
Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
8. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
9. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Blazina I; Selph S
Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
Khneizer G; Rizvi S; Gawrieh S
Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494
[TBL] [Abstract][Full Text] [Related]
12. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
13. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
Pár A; Wittmann I; Pár G
Orv Hetil; 2022 May; 163(22):855-862. PubMed ID: 35895614
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
[TBL] [Abstract][Full Text] [Related]
17. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
Yabiku K
Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
[TBL] [Abstract][Full Text] [Related]
19. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
[TBL] [Abstract][Full Text] [Related]
20. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]